Biohaven Ltd. (BHVN)

Current Report Filed: 2026-05-05

Biohaven has expanded its at-the-market (ATM) equity offering capacity to $350 million through Amendment No. 2, providing significant financial flexibility for funding operations, R&D, and potential acquisitions without near-term debt burden.
This is the second amendment to the original October 2023 equity distribution agreement in less than two years, suggesting the company may be actively utilizing or planning to utilize equity financing as a primary capital strategy.
The ATM offering provides the company discretionary control over timing and pricing of share issuance, reducing immediate dilution pressure compared to a traditional public offering, though cumulative dilution remains a consideration for existing shareholders.

Insider Trading Filed: 2026-03-19

Insider Kishan Mehta has disposed of 17,342 common shares of Biohaven Ltd. (BHVN), while also acquiring 17,342 shares indirectly through a family trust.
Mehta maintains direct ownership of 5,320 shares and indirect ownership of 17,342 shares through the trust, indicating ongoing involvement with the company.
The transaction suggests some portfolio rebalancing by Mehta, but the overall insider ownership position remains substantial, potentially signaling confidence in the company's prospects.

Annual Report Filed: 2026-03-02

Biohaven Ltd. (BHVN) has experienced steady revenue growth over the past 3 years, indicating a potentially strong market position for its products.
The company's net income has fluctuated significantly, raising concerns about its long-term profitability and the sustainability of its business model.
Biohaven's pipeline of product candidates appears promising, but the risks and uncertainties associated with their development and regulatory approval process could impact the company's future performance.

Current Report Filed: 2026-03-02

Biohaven Ltd. reported its financial results for Q4 and full-year 2025, indicating strong revenue and earnings growth compared to the previous year.
The company highlighted several key business developments, including the successful launch of a new pharmaceutical product and ongoing progress in its clinical trial pipeline.
Investors should closely monitor the company's continued execution, particularly as it relates to the performance of its new product and the advancement of its research and development initiatives.

Current Report Filed: 2026-01-12

Biohaven Ltd. is making an investor presentation on January 12, 2026, which may provide updates on the company's business and future plans.
The filing does not contain any information about financial results, product development, or other material business updates, indicating this may be a routine presentation.
As a British Virgin Islands-incorporated company, Biohaven Ltd. may have a different regulatory and disclosure environment compared to US-based pharmaceutical companies.

Current Report Filed: 2026-01-07

Biohaven Ltd. agreed to issue and sell 12.5 million common shares at $10 per share, raising $125 million in gross proceeds.
The share issuance is being conducted under the company's existing 'at-the-market' offering program, which was registered in October 2023.
The proceeds from this share sale will likely provide additional capital to fund the company's ongoing operations and pipeline development.

Insider Trading Filed: 2026-01-07

George C. Clark, VP and Chief Accounting Officer, has exercised 2,500 restricted share units and disposed of 1,117 shares to cover tax withholding, indicating ongoing equity ownership in the company.
Clark's indirect beneficial ownership of 20,000 common shares through an IRA suggests a long-term investment in Biohaven Ltd.
The vesting schedule of the restricted share units, with 2,500 shares vesting annually over the next 4 years, aligns Clark's incentives with long-term shareholder value creation.

Insider Trading Filed: 2026-01-07

The reporting person, Bruce Car, the Chief Scientific Officer of Biohaven Ltd., exercised 4,750 restricted share units and had 2,381 shares withheld to cover tax obligations, resulting in a net increase of 2,369 shares in his direct ownership.
Bruce Car also holds 30,000 Biohaven shares indirectly through an IRA, indicating he has a significant stake in the company.
The restricted share units were granted in January 2025 and vest in four equal installments over four years, aligning the reporting person's interests with long-term shareholder value creation.

Insider Trading Filed: 2026-01-07

The CEO, Vlad Coric, has exercised 14,250 restricted share units and sold 7,430 shares to cover tax withholding, indicating continued commitment to the company.
Coric owns a significant stake in Biohaven, with over 1.8 million shares held directly and another 2 million indirectly through family trusts, suggesting alignment with shareholder interests.
The vesting schedule of Coric's restricted share units, with four equal installments over the next four years, provides long-term incentive for the CEO to drive the company's success.

Insider Trading Filed: 2026-01-07

The reporting person, Matthew Buten, acquired 4,250 common shares of Biohaven Ltd. (BHVN) through the vesting of restricted share units on 01/05/2026.
Buten also had 2,594 shares withheld by the issuer to satisfy tax withholding requirements related to the vesting of the restricted share units.
Following the reported transaction, Buten beneficially owns 195,652 shares of Biohaven Ltd. common stock, including shares acquired through the employee share purchase plan.

Insider Trading Filed: 2026-01-07

Kimberly Gentile, the SVP of Clinical Operations at Biohaven Ltd. (BHVN), exercised 3,750 restricted share units and had 1,956 shares withheld to cover tax obligations, indicating continued confidence in the company's long-term prospects.
The insider transaction suggests Biohaven's management team believes in the company's growth potential, as Gentile's stake in the company increased to over 99,500 shares.
The vesting schedule of the restricted share units, with four equal installments over the next four years, aligns the executive's interests with long-term shareholder value creation.

Important Information